- Home
- ANGO vs NKTX Comparison
ANGO vs NKTX Comparison
Compare ANGO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- NKTX
- Stock Information
- Founded
- ANGO 1988
- NKTX 2015
- Country
- ANGO United States
- NKTX United States
- Employees
- ANGO N/A
- NKTX N/A
- Industry
- ANGO Medical/Dental Instruments
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- NKTX Health Care
- Exchange
- ANGO Nasdaq
- NKTX Nasdaq
- Market Cap
- ANGO 279.1M
- NKTX 225.1M
- IPO Year
- ANGO 2004
- NKTX 2020
- Fundamental
- Price
- ANGO $8.86
- NKTX $2.38
- Analyst Decision
- ANGO Strong Buy
- NKTX Strong Buy
- Analyst Count
- ANGO 4
- NKTX 5
- Target Price
- ANGO $12.00
- NKTX $15.20
- AVG Volume (30 Days)
- ANGO 615.8K
- NKTX 2.3M
- Earning Date
- ANGO 01-08-2025
- NKTX 11-07-2024
- Dividend Yield
- ANGO N/A
- NKTX N/A
- EPS Growth
- ANGO N/A
- NKTX N/A
- EPS
- ANGO N/A
- NKTX N/A
- Revenue
- ANGO $292,726,000.00
- NKTX N/A
- Revenue This Year
- ANGO N/A
- NKTX N/A
- Revenue Next Year
- ANGO $7.69
- NKTX N/A
- P/E Ratio
- ANGO N/A
- NKTX N/A
- Revenue Growth
- ANGO N/A
- NKTX N/A
- 52 Week Low
- ANGO $5.26
- NKTX $2.08
- 52 Week High
- ANGO $9.58
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- ANGO 61.62
- NKTX 35.48
- Support Level
- ANGO $8.45
- NKTX $2.08
- Resistance Level
- ANGO $9.58
- NKTX $2.39
- Average True Range (ATR)
- ANGO 0.49
- NKTX 0.22
- MACD
- ANGO 0.05
- NKTX 0.00
- Stochastic Oscillator
- ANGO 65.79
- NKTX 16.28
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.